| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20045027 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS20049925 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS20025509 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS20049443 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS44014966 | HTLV-1 | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DRD2 |
|---|---|
| DrugBank ID | DB01235 |
| Drug Name | Levodopa |
| Target ID | BE0000756 |
| UniProt ID | P14416 |
| Regulation Type | agonist |
| PubMed IDs | 17553470; 15710490; 15824260; 15728856; 18549347; 11978145; 9633680 |
| Citations | Dupre KB, Eskow KL, Negron G, Bishop C: The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 2007 Jul 16;1158:135-43. Epub 2007 May 8.@@Mori A, Ohashi S, Nakai M, Moriizumi T, Mitsumoto Y: Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res. 2005 Mar;51(3):265-74. Epub 2005 Jan 8.@@Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Ciro-Candiano IC, Gambardella A, Quattrone A: Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005 Apr;62(4):601-5.@@Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, Axelrod JD, Cheyette BN, Simon MI, Lester HA, Schwarz J: D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci. 2005 Feb 23;25(8):2157-65.@@Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 .@@Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309.@@Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. doi: 10.1212/wnl.50.6_suppl_6.s11. |
| Groups | Approved |
| Direct Classification | Tyrosine and derivatives |
| SMILES | N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O |
| Pathways | Tyrosine Metabolism; Disulfiram Action Pathway; Aromatic L-Aminoacid Decarboxylase Deficiency; Monoamine Oxidase-A Deficiency (MAO-A); Catecholamine Biosynthesis; Tyrosinemia, Transient, of the Newborn; Hawkinsinuria; Dopamine beta-Hydroxylase Deficiency; Tyrosinemia Type I; Alkaptonuria; Tyrosine Hydroxylase Deficiency |
| PharmGKB | PA450213 |
| ChEMBL | CHEMBL1009 |
